GLG Pharma Competitors

Shuttle Pharmaceuticals is a clinical-stage pharmaceutical company developing novel therapies and diagnostics to improve the outcomes for cancer patients treated with radiation therapy. Our technology sensitizes growing cancer cells, rendering them susceptible to the effects of radiation therapy, activates DNA damage and innate immune responses and offers the potential to integrate with checkpoint inhibitors and immune therapies. Our mass spectrometry-based diagnostics platform is focused on predicting clinical outcomes to inform clinical decisions for patients electing to receive radiation therapy for prostate cancer.

Cancer meets obesity - Metabolic dysfunction (obesity. diabetes, etc.) makes cancer more aggressive. SynDevRx is pioneering the metabo-oncology field with a first-in-class therapeutic targeting cancer patients with metabolic dysfunction. This overlooked patient population is estimated at >700,000/year in the US. We are in multiple Phase 2 clinical studies in breast cancer and prostate cancer with a unique value proposition. Our lead asset 'evexomostat' has dual action - anti-angiogenic/anti-tumor plus a potent and clinically validated metabolic correction activity.

A pioneer in immuno-modulation by cell specific delivery of oligonucleotide drugs to antigen presenting cells completing IND enabling studies for a groundbreaking anti-GVHD drug for hematopoietic stem cell transplantation in hematological cancers.